A

s experimental drugs continue to fail in Alzheimer’s patients, research interest has increasingly shifted to finding a way to stop the disease long before it erodes people’s cognitive abilities.

But how do you identify the right people to target?

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.